The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2026 | Neurological symptoms independently associated with worse prognosis for melanoma brain metastasis

Ariane Steindl • 26 Oct 2026

ESMO 2026

Melanoma Skin Cancer

Ariane Steindl, PhD, Medical University of Vienna, Vienna, Austria, discusses the association between neurological symptoms and overall survival in melanoma brain metastases, highlighting that around 50% of patients present with neurological symptoms at diagnosis, while the other 50% are asymptomatic. Patients with neurological symptoms were found to have a significantly worse prognosis, and this prognostic impact was independent of other factors, such as brain metastasis treatment and clinical characteristics. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.